Credits: Canva
An experimental treatment happens to be the solution to delay Alzheimer's symptoms in some people. These people are the ones who are genetically destined to get the disease in their 40s or 50s. These new findings form ongoing research has now been caught up in Trump administration funding delas. The early results of the study has been published on Wednesday and the participants too are worried that politics could cut their access to a possible lifeline.
One of the participants had said, "It is still a study but it has given me an extension to my life that I never banked on having." The participant is named Jake Henrichs, form New York City, who is 50 years old. He is one of them to be treated in that study for more than a decade now and has remained symptom-free despite inheriting an Alzheimer's-causing gene that had killed his father and brother around the same age.
Two drugs which can modestly slow down early-stage Alzheimer's are sold in the United States. These drugs clear the brain of one of its hallmarks, a sticky gunk-like part called the amyloid. However, there have not been any hints that removing amyloid far earlier, way many years before the first symptoms appear, may postpone the disease.
The research is led by Washington University in St Louis, which involved families that passed down rare gene mutation as participants. This meant it was almost guaranteed that they will develop symptoms at the same age their affected relatives did.
The new findings is based on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight years. Long-term amyloid removal cut in half their risk of symptom onset. The study is published in the journal Lancet Neurology.
Washington University's Dr Randall Bateman, who directs the Dominantly Inherited Alzheimer's Network of studies involving families with these rare genes says, "What we want to determine over the next five years is how strong is the protection. Will they ever get the symptoms of Alzheimer’s disease if we keep treating them?”
The researchers before though did not know what exactly caused Alzheimer's which affects nearly 7 million Americans, most of them in their later life. However, it is clear that these silent changes occur in the brain at least two decades before the first symptom shows up. The big contributor. At some point amyloid buildup can trigger a protein named tau that then starts to kill neurons, which can lead to cognitive decline.
Researchers are now thus studying the Tau-fighting drugs and are looking into other factors, like inflammation, brain's immune cells and certain virus.
The National Institute of Health (NIH) has expanded its focus as researchers have found more reasons for Alzheimer's. In 2013, the NIH's National Institute on Aging funded 14 trials of possible Alzheimer's drugs over a third targeting amyloid. By last fall, there were 68 drugs and 18% of them target amyloid. However, there are scientists too who think that amyloid is not everything and their is way more in the brain tissue, immune cells, and more which can be studied.
Credit: iStock
UK hospitals are seeing an increase in COVID-19 activity as the SARS-CoV-2 XFG variant, dubbed “American Covid” or “Stratus,” circulates in the country.
According to the latest data from the UK Health Security Agency (UKHSA), COVID positivity in hospital settings increased from 5.9% to 7.0%. The weekly hospital admission rate also rose from 0.81 to 1.20 per 100,000, an increase of about 48%.
London recorded the highest increase among regions, with its COVID hospital admission rate rising by 79%.
More than half of the sequenced positive samples were reported to be XFG. Among people aged over 85, hospital admission rates increased from 7.08 to 12.43 per 100,000.
However, the true number of infections could be higher because fewer people are testing for COVID-19 than during the pandemic.
Also read: Flu 2026: Symptoms To Watch For As New Season Begins
XFG is a recombinant SARS-CoV-2 variant formed from Omicron subvariants LF.7 and LP.8.1.2. The WHO records the earliest documented XFG sample on January 27, 2025, and designated it a variant under monitoring in June 2025.
The variant has since been detected in multiple countries and remains among the SARS-CoV-2 variants being monitored by WHO.
COVID symptoms can vary between individuals. Reported symptoms associated with the current circulation of XFG include:
Some people may also experience muscle and joint aches, gastrointestinal symptoms as well as eye or chest infections, while others may have no symptoms.
London GP Dr Renée Hoenderkamp has highlighted symptoms including sore throat, headache, runny nose, fatigue and flu-like aches, Daily Mail reported.
Read More: WHO Sets 2027 Flu Vaccine Strains; US States Can Now Order Free COVID Shots For Kids
There is currently no evidence that the variants circulating in the UK are causing more severe disease.
“There is no evidence that variants currently circulating in the UK are causing more severe disease,” Dr Siggins said. “However, COVID can still cause serious illness in those at greatest risk.”
The latest available figures cited in reports recorded seven deaths involving COVID in England in the week ending August 28, compared with six the previous week.
Older adults and people with underlying conditions remain more vulnerable to severe COVID.
The current increase is not comparable with the waves seen during the height of the COVID pandemic. UKHSA classifies the current hospital admission rate as being at a baseline level.
“COVID is increasing, but from a low level, which is not unexpected at this time of year,” said Dr Matthew Siggins, lecturer in immunity and infection biology at the University of Surrey, according to reports.
WHO has assessed the additional public health risk posed by XFG as low at the global level. Current evidence does not indicate that XFG causes more severe illness or deaths than other circulating variants.
People who develop a high temperature or feel particularly unwell should stay home and avoid contact with others while they recover.
People eligible for the autumn COVID vaccination are advised to get vaccinated to maintain protection against serious illness.
Most people have some immunity from previous infection, vaccination or both. However, immunity may decline over time and does not always prevent infection. Protection against severe disease is generally stronger.
WHO has said currently approved COVID vaccines are expected to continue providing protection against symptomatic and severe disease from XFG.
Credit: PIB
Robotic technology is set to become an accelerating tool across every specialty of medicine, covering diagnostics, treatment and therapy in India, Union Minister of State (Independent Charge) for Science & Technology Dr. Jitendra Singh said.
Speaking at the inaugural session of the International Conference of the Society of Robotic Surgery in New Delhi, Singh said robotics should not be viewed as technology limited to surgery but as a tool that could increasingly be used across different branches of medicine.
“It’s a tool. It will happen everywhere,” he said, adding that the future could see the emergence of robotic medicine, robotic endocrinology and robotic cardiology, just as AI is finding applications across medical specialties.
Singh said robotics, artificial intelligence (AI) and nanoscience could create a larger ecosystem for precision health delivery and precision medicine.
Emerging technologies, he said, could enable increasingly personalized healthcare based on an individual's genetic profile, environmental conditions, lifestyle and dietary patterns.
He said the next phase of medicine could see greater use of genetically driven diagnostics alongside advances in quantum technologies, nanomedicine, AI and robotics.
Singh also expressed a desire to launch gene sequencing for every newborn. Referring to the Genome India Program, he said 10,000 individuals have already been sequenced and that AI and robotics could support detailed genetic sequencing across India's population of 1.4 billion.
He also highlighted the potential of tele-robotics, sharing his experience of performing an ultrasound on a person located 10,000 kilometers away in Antarctica.
The shift toward robotic medicine is already visible in surgery. AIIMS experts recently explained how robotic technology is changing gallbladder surgery, building on the transition from open surgery to laparoscopy and now robotic-assisted procedures.
Professor Hemanga K Bhattacharjee, Department of Surgical Disciplines, AIIMS New Delhi, said inflammation, adhesions, scarring and unexpected anatomy can make gallbladder surgery difficult.
“What the surgeon encounters once the procedure begins can be very different from what was expected. In such situations, robotic-assisted surgery can be an ideal option, as the enhanced visualization and instrument control can help the surgeon navigate difficult anatomy with greater precision,” Bhattacharjee said.
The AIIMS Department of Surgical Disciplines uses the da Vinci robotic system, which provides a high-definition 3D view and wristed instruments for controlled movements. The department has performed more than 1,500 robot-assisted surgeries across specialties, according to hospital authorities.
Dr. Sunil Chumber, Head of the Department of Surgical Disciplines at AIIMS, Delhi, has worked through the evolution from open surgery and mini-laparotomy to laparoscopy and robotic-assisted surgery.
He described robotic-assisted surgery as “a significant step forward” and said he considers it “a superior surgical platform” based on his experience.
“My expectation is that, eventually, gallbladder surgery will be performed robotically and conventional laparoscopy will be phased out,” Chumber said.
“Every generation of surgery builds on what came before it. Laparoscopy was a major advancement in its time, but having worked with robotic-assisted surgery, I believe robotics is the next step in that evolution.”
Credit: Instagram
TikTok star Brooke Eby, who chronicled her life with amyotrophic lateral sclerosis (ALS), through candid, humorous and deeply personal videos, has died at 37.
Eby was diagnosed with ALS, also known as Lou Gehrig’s disease, in 2022 at age 33. ALS is a progressive neurodegenerative disease that damages the nerve cells responsible for voluntary muscle movement.
Eby became known for sharing the realities of living with ALS on social media. Her videos combined humor with candid accounts of how the disease affected her mobility, breathing, speech and daily life.
The ALS Network described her as an “extraordinary advocate, storyteller, community builder and friend” whose honesty and humor helped change how people understood ALS.
“Brooke changed the way people see ALS, but she also changed the way people living with ALS find and support one another,” said Sheri Strahl, president and CEO of the ALS Network.
Eby also used her platform to challenge the perception that ALS mainly affects older men.
“I didn’t choose ALS, but I did choose to get loud, and be irreverent about it,” Eby said after receiving an award from the ALS Network for her advocacy.
Eby regularly updated followers as her condition progressed.
In June 2025, she said her breathing capacity had declined significantly over six months. She also shared that she had undergone a procedure to have a feeding tube placed in her stomach.
By January 2026, Eby said she had begun experiencing bulbar symptoms, which can affect speech and swallowing. She reported trouble swallowing, speech disturbances and excess saliva.
In September 2026, she shared that her speech had deteriorated rapidly.
“In the last few weeks, people just can’t understand me at all,” she said, explaining that speaking had also begun requiring careful positioning of her body.
In a PEOPLE essay, Eby wrote that she wanted people to understand that ALS does not discriminate by age, gender or demographic.
“I have ALS at a relatable age. Personally, I always associated this disease with older men,” she wrote. “But I could be someone’s daughter, sister, mom, girlfriend, wife.”
While much of her content was comedic, Eby also educated her audience about ALS, including how symptoms can vary and how the disease progresses.
ALS affects motor neurons in the brain and spinal cord that control voluntary muscle movement. As these nerve cells degenerate, people can develop muscle weakness, loss of movement, difficulty speaking and swallowing, and eventually breathing problems.
ALS can begin in the limbs or with speech and swallowing problems, known as bulbar-onset ALS.
There is currently no cure for ALS, although treatments can help manage symptoms, improve quality of life and extend survival.
Symptoms vary but can include:
Some people with ALS also develop cognitive or behavioral changes.
Eby’s social media posts gave thousands of followers a candid look at how the disease could change everyday life, while helping raise awareness about a condition that is often associated with older adults.
© $2026 Times Horizon Private Limited